^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    STI-8591

    i
    Other names: STI-8591, AC0939, AC-0939, AC 0939
    Company:
    Sorrento
    Drug class:
    FLT3 inhibitor
    Related drugs:
    2ms
    Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics. (PubMed, Eur J Med Chem)
    First-generation multi-kinase inhibitors like midostaurin and second-generation agents such as gilteritinib and quizartinib have shown success. It discusses how these agents, including small-molecule like STI-8591, compounds 36 and 80 and novel therapeutic strategies such as CLN-049, and SENTI-202, are designed to combat resistance. The goal is to provide a medicinal chemistry perspective to provide insights for the design of novel small-molecule FLT3i.
    Review • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • midostaurin • Vanflyta (quizartinib) • STI-8591 • CLN-049
    9ms
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd. | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591
    almost2years
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591
    almost2years
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd. | Initiation date: Sep 2023 --> Mar 2024
    Trial initiation date • Metastases
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591
    over2years
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd.
    New P1 trial • Metastases
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591